Oncology Assessment for Biosimilar In-licensing

Leah Hoffmann

The head of marketing for a biopharma company’s biosimilars business unit was struggling to size two oncology in-licensing opportunities in the U.S. and Europe. Looking for an informed assessment—and a broader picture of biosimilar developments in the oncology market—she turned to Business Talent Group.

Our consultant had a PhD in Chemistry and an MBA from London Business School; he’d worked as a Project Leader in BCG’s healthcare practice and led Drug Discovery and Early Clinical Development at Sanofi. First, he outlined key oncology customer segments, reimbursement and formulary stakeholders, and market dynamics and drivers for the two target molecules. Then he used the company’s internal financial valuation model to inform a go/no-go decision.

 

Previous Article
Consolidating Fleet and Freight Vendors
Consolidating Fleet and Freight Vendors

The procurement group at a medical device manufacturer was implementing a major cost reduction initiative. ...

Next Article
ERP Redesign
ERP Redesign

The VP of strategy at one of a food and beverage giant’s best-loved brands had commissioned an enterprise r...